Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
- PMID: 23065360
- DOI: 10.1093/rheumatology/kes289
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
Abstract
Objectives: In a multi-centre study, we sought to determine whether extent of disease on high-resolution CT (HRCT) lung, reported using a simple grading system, is predictive of decline and mortality in SSc-related interstitial lung disease (SSc-ILD), independently of pulmonary function tests (PFTs) and other prognostic variables.
Methods: SSc patients with a baseline HRCT performed at the time of ILD diagnosis were identified. All HRCTs and PFTs performed during follow-up were retrieved. Demographic and disease-related data were prospectively collected. HRCTs were graded according to the percentage of lung disease: >20%: extensive; <20%: limited; unclear: indeterminate. Indeterminate HRCTs were converted to limited or extensive using a forced vital capacity threshold of 70%. The composite outcome variable was deterioration (need for home oxygen or lung transplantation), or death.
Results: Among 172 patients followed for mean (s.d.) of 3.5 (2.9) years, there were 30 outcome events. In Weibull multivariable hazards regression modelling, baseline HRCT grade was independently predictive of outcome, with an adjusted hazard ratio (aHR) = 3.0, 95% CI 1.2, 7.5 and P = 0.02. In time-varying covariate models (based on 1309 serial PFTs and 353 serial HRCTs in 172 patients), serial diffusing capacity of the lung for carbon monoxide by alveolar volume ratio (ml/min/mmHg/l) (aHR = 0.4; 95% CI 0.3, 0.7; P = 0.001) and forced vital capacity (dl) (aHR = 0.9; 95% CI 0.8, 0.97; P = 0.008), were also strongly predictive of outcome.
Conclusion: Extensive disease (>20%) on HRCT at baseline, reported using a semi-quantitative grading system, is associated with a three-fold increased risk of deterioration or death in SSc-ILD, compared with limited disease. Serial PFTs are informative in follow-up of patients.
Similar articles
-
Predictors of progression in systemic sclerosis patients with interstitial lung disease.Eur Respir J. 2020 May 14;55(5):1902026. doi: 10.1183/13993003.02026-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32079645 Free PMC article. Review.
-
Interstitial lung disease in systemic sclerosis: a simple staging system.Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54. doi: 10.1164/rccm.200706-877OC. Epub 2008 Mar 27. Am J Respir Crit Care Med. 2008. PMID: 18369202 Clinical Trial.
-
Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.Semin Arthritis Rheum. 2017 Oct;47(2):228-234. doi: 10.1016/j.semarthrit.2017.03.019. Epub 2017 Apr 1. Semin Arthritis Rheum. 2017. PMID: 28454677
-
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S111-6. Epub 2015 Aug 5. Clin Exp Rheumatol. 2015. PMID: 26243401
-
[Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].Rev Pneumol Clin. 2014 Dec;70(6):335-42. doi: 10.1016/j.pneumo.2014.09.003. Epub 2014 Nov 20. Rev Pneumol Clin. 2014. PMID: 25457218 Review. French.
Cited by
-
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.J Scleroderma Relat Disord. 2022 Oct;7(3):168-178. doi: 10.1177/23971983211064463. Epub 2022 Jan 3. J Scleroderma Relat Disord. 2022. PMID: 36211204 Free PMC article. Review.
-
Management of systemic sclerosis-associated interstitial lung disease.Curr Opin Rheumatol. 2019 May;31(3):241-249. doi: 10.1097/BOR.0000000000000592. Curr Opin Rheumatol. 2019. PMID: 30870216 Free PMC article. Review.
-
Predictors of progression in systemic sclerosis patients with interstitial lung disease.Eur Respir J. 2020 May 14;55(5):1902026. doi: 10.1183/13993003.02026-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32079645 Free PMC article. Review.
-
Personalized medicine in systemic sclerosis: facts and promises.Curr Rheumatol Rep. 2014 Jun;16(6):425. doi: 10.1007/s11926-014-0425-8. Curr Rheumatol Rep. 2014. PMID: 24752884 Review.
-
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.Rheumatology (Oxford). 2023 May 2;62(5):1870-1876. doi: 10.1093/rheumatology/keac535. Rheumatology (Oxford). 2023. PMID: 36111858 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical